PolyPid (PYPD) deputy CEO discloses extensive employee stock options
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
PolyPid Ltd. deputy CEO and EVP R&D Hazan Dalit Fellous has filed an initial Form 3 reporting holdings of employee stock options over the company’s ordinary shares. The filing lists multiple option grants with exercise prices ranging from 2.6700 to 92.8900 per share and expirations between 2026 and 2035.
Several grants are disclosed as fully vested based on earlier grant dates, while others vest on a quarterly schedule through dates such as May 9, 2026, August 7, 2027, May 6, 2028, and May 12, 2029. This Form 3 records existing derivative holdings and does not show any new purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
12 transactions reported
Mixed
12 txns
Insider
Hazan Dalit Fellous
Role
Deputy CEO, EVP, RD, CRA
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Employee Stock option (right to buy) — 73 shares (Direct)
Footnotes (1)
- The options were granted on April 5, 2016 and fully vested as of April 5, 2019. The options were granted on August 24, 2016 and fully vested as of August 24, 2019. The options were granted on November 2, 2017 and fully vested as of November 2, 2020. The options were granted on February 6, 2020 and fully vested as of February 6, 2023. The options were granted on June 11, 2020 and fully vested as of June 11, 2024. The options were granted on May 9, 2022 and vest on a quarterly basis beginning May 9, 2023 until May 9, 2026. The options were granted on August 9, 2021 and fully vested as of August 9, 2025. The options were granted on August 7, 2023 and vest on a quarterly basis beginning August 7, 2024 until August 7, 2027. The options were granted on May 6, 2024 and vest on a quarterly basis until May 6, 2028. The options were granted on May 6, 2024 and vest on a quarterly basis until May 6, 2026. The options were granted on May 12, 2025 and vest on a quarterly basis until May 12, 2029. The options were granted on May 12, 2025 and vest on a quarterly basis until May 12, 2027.
FAQ
What does PolyPid (PYPD) deputy CEO report in this Form 3?
The deputy CEO reports existing employee stock options over PolyPid ordinary shares. These options have various exercise prices, expiration dates, and vesting schedules, documenting her current derivative holdings rather than new market transactions.
What option exercise prices are disclosed for PolyPid (PYPD) deputy CEO?
The filing lists several exercise prices, including 92.8900, 23.0700, 11.0100, 4.6400, and 2.6700 per share. These apply to different option grants over PolyPid ordinary shares with distinct vesting and expiration dates.
When do the reported PolyPid (PYPD) options held by the deputy CEO expire?
The options expire on various dates from 2026 through 2035. Specific expirations include April 5, 2026, August 24, 2026, November 2, 2027, and later dates such as May 6, 2034 and May 12, 2035 for newer grants.
How do PolyPid (PYPD) deputy CEO’s options vest according to the Form 3 footnotes?
Footnotes show some grants are fully vested, tied to dates like April 5, 2019 and August 9, 2025. Others vest on a quarterly basis through schedules ending May 9, 2026, August 7, 2027, May 6, 2028, and May 12, 2029.
What types of securities are reported in the PolyPid (PYPD) Form 3 for the deputy CEO?
The Form 3 reports only employee stock options (rights to buy) as derivative securities. Each option grant is linked to a number of underlying PolyPid ordinary shares, with detailed exercise prices, vesting terms, and expiration dates.